JPRN-UMIN000019030
Completed
未知
Multicenter clinical study of immune-cell therapy in patients with malignant tumors. - Multicenter clinical study of immune-cell therapy in patients with malignant tumors.
KOUSHIKAI,Non-profitmedicalcorporation0 sites1,800 target enrollmentSeptember 27, 2015
ConditionsMalignant tumor
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Malignant tumor
- Sponsor
- KOUSHIKAI,Non-profitmedicalcorporation
- Enrollment
- 1800
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) HIV Ab positive. 2\) T cell\- or NK cell\-originated leukemia and/or lymphoma.(LAK therapy) 3\)Patients who have previously treated allogenic transplantation. 4\) Responsible doctors judged the patient inappropriate for the clinical study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
A clinical study on the safety of immune-cell therapy combined with standard therapy for high-grade gliomagliomaJPRN-UMIN000032147Juntendo University Faculty of Medicine5
Active, not recruiting
Not Applicable
Phase II multicenter study of immuno-chemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) for symptomatic Waldenstrom's macroglobulinemiaEUCTR2005-000174-52-ITASSOCIAZIONE MALATTIE SANGUE
Active, not recruiting
Not Applicable
Multicentre trial evaluating the immunogenicity of HPV vaccination in girls on immunosuppressive therapy. - PRIMAVERAInfection by HPV 6, 11, 16, 18Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2011-006002-27-FRCHU de Bordeaux
Completed
Phase 1
Phase I Trial of Combined Immune Cell Therapy for Metastatic Stage IV Solid Tumors (SDH-Combi)NCT06296056Seoul Hospital9
Completed
Phase 1
A phase I clinical study of immune cell therapy with MAGE-A4- or Survivin-specific Th1 cells for patients with refractory virulent tumorsRefractory cancer patients (MAGE-A4- or Survivin-expressing, non origin-limited) or the patients who refuse standard cancer therapyJPRN-UMIN000004828Department of General Surgery, Hokkaido University Graduated School of Medicine18